Skip to main content

Clinical Trials

Patients play a central role in research. ‎They are key partners in advancing medical knowledge that improves the lives of those living with kidney disease.

Current Studies

You can contribute by participating in one of our current research studies.

C3G: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients with C3 Glomerulopathy 

In C3 glomerulopathy, the complement system, which is part of the immune system, is not regulated appropriately. This leads to over-activation of the system, resulting in deposition of complement products in the filtration units of the kidney. Currently, there is no approved drug treatment for patients with C3 glomerulopathy. Immunosuppressive drugs such as cyclophosphamide, mycophenolate mofetil, and glucocorticoids, as well as biologics such as rituximab have been used with limited success.

One way to treat C3 glomerulopathy may be to regulate the action of a specific protein that is part of the complement system called C5a on its receptor C5aR. Avacopan is a drug that selectively targets this C5aR and blocks the activity of C5a. 

For more information, click here or email

EMPA-KIDNEY Study: A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease 

Chronic Kidney Disease (CKD) is caused by many different things, including increasing age. Diabetes, high blood pressure, inflammation in the kidney and inherited diseases are the most common causes in Canada. It is known that people with CKD are both at risk of their kidney problem worsening and developing heart problems.

The purpose of this study is to find out if taking a single pill of empagliflozin every day prevents worsening of kidney disease or deaths from heart disease in people who have kidney disease. Empagliflozin has been shown to have beneficial effects on both the heart and kidney in diabetics. 

For more information, click here or email

The SPOR Canadian GN Registry (CGNR) and Translational Research Initiative  
GN is a group of rare diseases (<5 per 250,000 population), yet is a leading cause of kidney failure and accounts annually for close to 20 % of new cases of end stage kidney disease (ESKD) in Canada. Prevention of progression to kidney failure is possible, however there are several barriers and gaps in knowledge that challenge the ability to provide patients with individualized effective therapy. 

We are collaborating with other centers across Canada to address these challenges.  We will create a registry by enrolling a large group of patients across the country with these types of glomerulonephritis: MCD (minimal change disease), FSGS (Focal and segmental glomerulosclerosis), MN (Membranous nephropathy), Mesangioproliferative Glomerulonephritis (MPGN) or IgAN (Immunoglobulin A nephropathy).  Participation would involve a hospital visit twice a year over a 2 year period to collect medical information, demographics (such as age and gender), as well as blood and urine samples.  Having this source of data will be an invaluable resource for national collaborative translational research in this rare disease. 

For more information, email

Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A Nephropathy (IgAN), is the most common cause of glomerulonephritis worldwide, and causes end-stage renal disease (ESRD) in a significant percentage of patients; however there is currently no optimal management strategy for IgAN. Therapeutic options include treatment to reduce blood pressure and protein in the urine (proteinuria, which is a sign of kidney damage) .  For patients with protein in their urine (proteinuria), despite rigorous blood pressure control, immunosuppressive agents such as corticosteroids or cyclophosphamide may also be added. Although these drugs may lower the risk of kidney disease progression and the need for dialysis and transplantation, their use is limited because of their well-known adverse effects. The Kidney Disease Improving Global Outcomes (KDIGO) guidelines make suggestions for treatment, however they are simply suggestions.  No disease-specific therapies are currently available, and an unmet need persists for novel interventions, particularly in patients who are at risk of progressive disease that can result in end-stage renal failure.

Due to the unmet need for new treatment in IgAN, there are many new studies looking at different study drugs for this disease. For more information, email or   If a nephrologist thinks that participation in a research study could be beneficial for an IgAN patient, they could make a referral to the clinic of Sean Barbour, who is the Principal Investigator for these studies and the person who is best equipped to decide which if any of these studies would be most suitable and appropriate for each individual's specific set of circumstances.   

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (Artemis-IGAN)   

This study will test a new investigational drug referred to as OMS721.  During the study, all patients will continue with their current treatment for IgAN and will also receive either the study drug or placebo. Each dose of the study drug or placebo will be given via a 30-minute intravenous infusion (through a vein, also known as IV) once a week for 12 weeks at St. Paul’s Hospital.  After a period of response evaluation, another 12 weeks of treatment (drug or placebo) may be possible if the response was not optimal.

For more information, click here or email

A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease  

The overall aim of the study is to evaluate the efficacy, safety, and tolerability of Nefecon 16 mg per day.   Nefecon is a capsule specially modified to deliver the active ingredient budesonide locally in the small intestine. Budesonide is a well known substance and has been used for over 10 years for example in asthma and Crohn’s disease and for respiratory indications since 1981.  Subjects will receive either the study drug or placebo for this study.  Subjects in this study will go home with the bottles of this medication to be taken orally for 9 months.

For more information, click here or email

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Cemdisiran in Adult Patients with IgA Nephropathy
The investigational drug or placebo for this study will be by sub-cutaneous (under the skin) injection every 4 weeks for 9 months.  At the end of the treatment period, subjects will have the option to receive the investigational drug (not placebo) every 4 weeks for an additional year 52 weeks).

For more information, click here or email

An Open-Label Phase 2a Clinical Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Subjects with Primary IgA Nephropathy
This research project is testing an experimental drug for IgA Nephropathy called ISIS 696844.  This is the first time ISIS 696844 is being tested in patients with IgA Nephropathy. ISIS 696844 has been tested in two healthy volunteer studies previously.  Everyone in this study will receive the study drug by sub-cutaneous (under the skin) injection, eight times over a 24 week treatment period. No one will receive placebo.

For more information, click here or email

For more information regarding different types of clinical studies, reasons to participate and what to expect, please visit the PHSA website.  

Tab Heading
Tab Heading
Tab Heading
Tab Heading
SOURCE: Clinical Trials ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Renal Agency. All Rights Reserved.

    Copyright © 2021 Provincial Health Services Authority